Product Overview
The Human CDO1 and HOXA9 Gene Methylation Detection Kit is an in vitro qualitative diagnostic assay employing real-time fluorescent PCR to test methylation levels of CDO1 and HOXA9 genes in human plasma (cell-free DNA). It is a non-invasive blood-based screening tool for the early detection of lung cancer, targeting high-risk populations such as heavy smokers and individuals with occupational exposure. ### Key Features - **Liquid biopsy for lung cancer screening:** cfDNA
Key Features & Advantages
- time fluorescent PCR to test methylation levels of CDO1 and HOXA9 genes in human plasma (cell - free DNA). It is a non - invasive blood - based screening tool for the early detection of lung cancer, targeting high - risk populations such as heavy smokers and individuals with occupational exposure. ### Key Features - - Liquid biopsy for lung cancer screening: - cfDNA methylation analysis from peripheral blood.
Clinical Applications
Clinical laboratories, hospitals, public health departments, and diagnostic testing centers for infectious disease detection.
Comparison & Competitive Advantages
Unlike conventional culture methods that require 48-72 hours for results, this real-time PCR kit delivers definitive pathogen detection in under 2 hours. The molecular method offers superior analytical sensitivity, detecting low-copy-number targets that culture may miss.
Technical Specifications
Sample: type:** Plasma from cell-free DNA blood collection tubes. - **Platform:** Standard real-time PCR instruments (ABI, Bio-Rad, Roche). - **Turnaround time:** ~3 hours from plasma to result. ### Clinical Applications - Lung cancer screening in high-risk populations (smoking history ≥ 30 pack-years) - Supplemental testing for indeterminate pulmonary nodules detected by LDCT - Pre-operative molecular profiling adjunct - Post-surgical recurrence surveillance ### Comparative Advantage Low-dose CT (LDCT) is the current gold standard for lung cancer screening but suffers from a high false-positive rate (96% of nodules are benign) and cumulative radiation exposure. CDO1/HOXA9 methylation testing provides a radiation-free, blood-based alternative with higher specificity — potentially reducing unnecessary invasive follow-up procedures in nodule management. ### Comparative Advantages Unlike conventional cytology screening and HPV DNA testing that indicate risk but not actual disease progression, this methylation-based detection kit provides direct molecular evidence of malignant transformation at the epigenetic level. Compared to colposcopy-guided biopsy which is invasive and operator-dependent, this non-invasive real-time PCR assay offers faster turnaround with equivalent clinical sensitivity for high-grade lesion detection, enabling earlier clinical decision-making and more efficient patient triage. ### Quality & Compliance CE-IVD marked. ISO 13485 certified. Validated in clinical cohorts.
sensitivity: for high-grade lesion detection, enabling earlier clinical decision-making and more efficient patient triage. ### Quality & Compliance CE-IVD marked. ISO 13485 certified. Validated in clinical cohorts.
current: gold standard for lung cancer screening but suffers from a high false-positive rate (96% of nodules are benign) and cumulative radiation exposure. CDO1/HOXA9 methylation testing provides a radiation-free, blood-based alternative with higher specificity — potentially reducing unnecessary invasive follow-up procedures in nodule management. ### Comparative Advantages Unlike conventional cytology screening and HPV DNA testing that indicate risk but not actual disease progression, this methylation-based detection kit provides direct molecular evidence of malignant transformation at the epigenetic level. Compared to colposcopy-guided biopsy which is invasive and operator-dependent, this non-invasive real-time PCR assay offers faster turnaround with equivalent clinical sensitivity for high-grade lesion detection, enabling earlier clinical decision-making and more efficient patient triage. ### Quality & Compliance CE-IVD marked. ISO 13485 certified. Validated in clinical cohorts.
Frequently Asked Questions
Q: What is the detection limit of this Human CDO1 and HOXA9 Gene Methylation Detection kit（Real-time PCR） PCR kit?
A: The kit achieves a limit of detection (LOD) of approximately 5 copies per reaction, enabling sensitive identification of low-level infections. This molecular method is significantly more sensitive than conventional culture or antigen-based approaches.
Q: What sample types are compatible with this kit?
A: This kit is optimized for the appropriate clinical specimen type (e.g., stool, blood, swab). The integrated internal control monitors extraction efficiency and detects PCR inhibition, ensuring reliable results across different sample matrices.
Q: How long does the PCR test take?
A: The real-time PCR assay delivers results in approximately 2 hours, compared to 48-72 hours required for conventional culture-based methods. This enables same-day clinical decisions and faster outbreak response.
Q: What instruments is this kit compatible with?
A: The kit is compatible with mainstream real-time PCR instruments including Applied Biosystems 7500, QuantStudio 5, Roche LightCycler 480, Bio-Rad CFX96, QIAGEN Rotor-Gene Q, and Analytik Jena qTOWER3.
← Back to all products